We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Mawi DNA

Mawi DNA Technologies develops unique biosample collection technologies enabling universal sample collection from any... read more Featured Products: More products

Download Mobile App




Whole Blood Collection Technology Enables Isolation of cfDNA, CTC, and RNA from Same Sample

By LabMedica International staff writers
Posted on 03 Aug 2022
Print article
Image: HemaSure-OMICs collection tubes (Photo courtesy of Mawi DNA)
Image: HemaSure-OMICs collection tubes (Photo courtesy of Mawi DNA)

RNA is a crucial tool in advancing our understanding of health and disease in humans and animals. However, RNA is particularly fragile and degrades quickly as soon the cells leave the internal environment of the body, such as when blood is drawn. A reliable technology to stabilize the sample right after collection is needed to reduce the degradation rate and maintain RNA integrity for proper analysis. Currently, efficient stabilization of RNA in body fluids, cells or tissues requires expensive cold chain involvement or relatively toxic fixative, which increases the cost per sample and urgency for processing the sample, leaving very little room for error. Whole blood can be a great source of stable RNA. However, commercially available whole blood collection tubes for RNA stabilization have certain limitations. Now, a groundbreaking product for ambient collection, stabilization, and transportation of whole blood samples enables isolation of cfDNA, CTC, and RNA from the same sample. Collected cells are maintained intact, making them also suitable for FACS analysis.

In order to overcome existing hurdles and enable widespread and efficient collection and analysis of whole blood, Mawi DNA Technologies (Hayward, CA, USA) has developed the HemaSure-OMICs Collection Tube products that offer non-toxic stabilization of whole blood, free of formaldehyde or formaldehyde-like ingredients. HemaSure-OMICs Whole Blood Collection Tubes are validated for room temperature stabilization of viral DNA and RNA for several days in viral load and detection assays applicable to the HIV, MERS-CoV, 2019-nCoV and other DNA and RNA viruses.

cfDNA (up to 14 days), CTC (up to 8 days), and RNA (up to 8 days) are stabilized at room temperature in the same blood tube (temperature range of 25° – 45° C). HemaSure-OMICs Whole Blood Collection Tubes are available in 3, 6, and 9 mL plastic vacuum filled blood collection tubes as well as a 250µl microtainer for blood drops for easy shipping and durability. They are compatible with any commercially available manual or automation-enabled kits for the purification of cfDNA and CTC from whole blood. HemaSure-OMICs Whole Blood Collection Tubes are for research use only and not for use in diagnostic or therapeutic procedures.

Related Links:
Mawi DNA Technologies

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.